<p>Supplementary Material (online only)</p><p>Supplementary Table S1. Studies Included in the Analysis (online only) </p><p>Study Citation Study Phase Study Population Chemotherapy Regimen Pegfilgrastim versus filgrastim RCTs Holmes et al., 2002 2 Breast doxorubicin + docetaxel Holmes et al., 2002 3 Breast doxorubicin + docetaxel Green et al., 2003 3 Breast doxorubicin + docetaxel Grigg et al., 2003 2 NHL CHOP Lopez et al., 2004 2 NHL CHOP-R Vose et al., 2003 2 NHLa ESHAP Johnston et al., 2000 2 NSCLC carboplatin + paclitaxel Pegfilgrastim versus no G-CSF RCTs Vogel et al., 2005 3 Breast docetaxel Romieu et al., 2007 2 Breast FEC-100 Hecht et al., 2010 2 Colorectal FOIL, FOLFOX4, FOLFIRI Smith et al., 2005 4 NSCLC carboplatin + paclitaxel + docetaxel Balducci et al., 2007 4 NHL, lung, breast, various or ovarian Same-day pegfilgrastim versus next-day pegfilgrastim studiesb Burris et al., 2010 2 NHL, breast, various ovarian, or lungc Single-arm studies Mattioli et al., 2009 2 Breast CMF George et al., 2003 2 NHL CHOP Wolf et al., 2006 2 NHL CHOP Pirker et al., 2006 2 SCLC ACE AMG 990736 (data on file) 2 Mixedd various AMG 20010137 (data on file) 2 Breast various aFour patients in this study had Hodgkin’s lymphoma but were grouped with the patients with NHL because they received ESHAP chemotherapy. bOnly patient data from the next-day arm were included in the analysis. cThese were four phase 2 studies that separately enrolled patients with NHL or breast, ovarian or lung cancer. dFive patients with tumor types reported as “other” were excluded. ACE, doxorubicin, cyclophosphamide, and etoposide; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; CHOP-R, CHOP and rituximab; CMF, cyclophosphamide, methotrexate, 5-fluorouracil; ESHAP, etoposide, methylprednisolone, cisplatin, and cytarabine; FEC-100, 5-fluorouracil, epirubicin, and cyclophosphamide; FOIL, 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan; FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan; FOLFOX4, 5-fluorouracil, leucovorin, and oxaliplatin; G-CSF, granulocyte colony-stimulating factor; NHL, non-Hodgkin’s lymphoma; RCTs, randomized controlled trials; SCLC, small-cell lung cancer.</p><p>1</p>